Asymmetric Dimethylarginine (ADMA) Has a Role in Regulating Systemic Vascular Tone in Young Healthy Subjects: The Cardiovascular Risk in Young Finns Study | Zendy

Hannu Päivä | Zendy; Mika Kähönen | Zendy; Terho Lehtimäki | Zendy; Olli T. Raitakari | Zendy; Antti Jula | Zendy; Jorma Viikari | Zendy; Georg Alfthan | Zendy; Markus Juonala | Zendy; R. Laaksonen | Zendy; Nina HutriKähönen | Zendy

Open Access

Asymmetric Dimethylarginine (ADMA) Has a Role in Regulating Systemic Vascular Tone in Young Healthy Subjects: The Cardiovascular Risk in Young Finns Study

Author(s) -

Hannu Päivä,

Mika Kähönen,

Terho Lehtimäki,

Olli T. Raitakari,

Antti Jula,

Jorma Viikari,

Georg Alfthan,

Markus Juonala,

R. Laaksonen,

Nina HutriKähönen

Publication year - 2008

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2008.215

Subject(s) - asymmetric dimethylarginine , medicine , vascular resistance , hemodynamics , blood pressure , pulse wave velocity , cardiology , endocrinology , arginine , biochemistry , chemistry , amino acid

This study was designed to evaluate whether plasma asymmetric dimethylarginine (ADMA) has any role in predicting hemodynamic responses in clinically healthy young subjects. ADMA, as an endogenous nitric oxide (NO) synthase inhibitor, has been demonstrated to associate with hypertension and vascular reactivity in experimental but not undoubtedly in physiological settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research